RaDaR® ST for Pharma Partners
Tumor-informed MRD, enhancing precision therapy development through deep molecular insights
The RaDaR ST Approach
RaDaR ST delivers high-sensitivity, personalized detection of molecular residual disease (MRD)
*LOD = Limit of detection
The RaDaR ST assay
Streamlined workflow for actionable MRD insights
RaDaR ST utilizes whole exome sequencing (WES) data from tumor samples and bioinformatic pipelines to develop bespoke MRD panels. The RaDaR ST approach leverages high-depth sequencing with personalized panels to achieve highly sensitive and specific ctDNA detection from plasma samples.
MRD testing can help to accelerate clinical development
MRD Utility
Enriching Trial Populations
Tab content
Therapeutic Monitoring
Tab content
Surrogate Endpoints
Tab content
Get in touch
Get in touch
Our Pharma Services team would love to further the discussion.
CTA style
Default